scispace - formally typeset
Search or ask a question
Institution

University of Vermont

EducationBurlington, Vermont, United States
About: University of Vermont is a education organization based out in Burlington, Vermont, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 17592 authors who have published 38251 publications receiving 1609874 citations. The organization is also known as: UVM & University of Vermont and State Agricultural College.


Papers
More filters
Journal ArticleDOI
TL;DR: In this article, the stability of solitons in parity-time (PT)-symmetric periodic potentials (optical lattices) is analyzed in both one-and two-dimensional systems.
Abstract: Stability of solitons in parity-time (PT)-symmetric periodic potentials (optical lattices) is analyzed in both one- and two-dimensional systems First we show analytically that when the strength of the gain-loss component in the PT lattice rises above a certain threshold (phase transition point), an infinite number of linear Bloch bands turn complex simultaneously Second, we show that while stable families of solitons can exist in PT lattices, increasing the gain-loss component has an overall destabilizing effect on soliton propagation Specifically, when the gain-loss component increases, the parameter range of stable solitons shrinks as new regions of instability appear Third, we investigate the nonlinear evolution of unstable PT solitons under perturbations, and show that the energy of perturbed solitons can grow unbounded even though the PT lattice is below the phase transition point

286 citations

Journal ArticleDOI
TL;DR: Sutton et al. as discussed by the authors investigated the contributions of four basic types of capital (human, social, built, and natural) to life satisfaction and proposed a National Well-Being Index (NWI) based on their findings.

286 citations

Journal ArticleDOI
TL;DR: This review highlights recent targeted approaches towards improving microbial tolerance to next-generation biofuels with a particular emphasis on strategies that will improve production.
Abstract: A major challenge when using microorganisms to produce bulk chemicals such as biofuels is that the production targets are often toxic to cells. Many biofuels are known to reduce cell viability through damage to the cell membrane and interference with essential physiological processes. Therefore, cells must trade off biofuel production and survival, reducing potential yields. Recently, there have been several efforts towards engineering strains for biofuel tolerance. Promising methods include engineering biofuel export systems, heat shock proteins, membrane modifications, more general stress responses, and approaches that integrate multiple tolerance strategies. In addition, in situ recovery methods and media supplements can help to ease the burden of end-product toxicity and may be used in combination with genetic approaches. Recent advances in systems and synthetic biology provide a framework for tolerance engineering. This review highlights recent targeted approaches towards improving microbial tolerance to next-generation biofuels with a particular emphasis on strategies that will improve production.

286 citations

Journal ArticleDOI
TL;DR: Treatment algorithms are presented to help guide the management of patients with CDI, including a toxin-binding polymer, tolevamer; 2 poorly absorbed antimicrobials, OPT-80 and ramoplanin; monoclonal antibodies; and a C. difficile vaccine.
Abstract: Recent outbreaks of Clostridium difficile infection (CDI) in North America have been due to a more virulent, possibly more resistant strain that causes more-severe disease, making prompt recognition of cases and optimal management of infection essential for a successful therapeutic outcome. Treatment algorithms are presented to help guide the management of patients with CDI. Metronidazole has been recommended as initial therapy since the late 1990s and continues to be the first choice for all but seriously ill patients and those with complicated or fulminant infections or multiple recurrences of CDI, for whom vancomycin is recommended. Other options for recurrent CDI, such as probiotics and currently available anion-exchange resins, have limited efficacy and are potentially harmful. Intravenous immunoglobulin may benefit patients with refractory, recurrent, or severe disease, but no controlled data are available. Two antimicrobials available in the United States for other indications, nitazoxanide and rifaximin, have been used successfully for CDI treatment but, like metronidazole, lack United States Food and Drug Administration approval for this indication. Experimental treatments currently in clinical development include a toxin-binding polymer, tolevamer; 2 poorly absorbed antimicrobials, OPT-80 (formerly known as Difimicin) and ramoplanin; monoclonal antibodies; and a C. difficile vaccine.

285 citations


Authors

Showing all 17727 results

NameH-indexPapersCitations
Albert Hofman2672530321405
Ralph B. D'Agostino2261287229636
George Davey Smith2242540248373
Stephen V. Faraone1881427140298
Valentin Fuster1791462185164
Dennis J. Selkoe177607145825
Anders Björklund16576984268
Alfred L. Goldberg15647488296
Christopher P. Cannon1511118108906
Debbie A Lawlor1471114101123
Roger J. Davis147498103478
Andrew S. Levey144600156845
Jonathan G. Seidman13756389782
Yu Huang136149289209
Christine E. Seidman13451967895
Network Information
Related Institutions (5)
University of Minnesota
257.9K papers, 11.9M citations

97% related

Duke University
200.3K papers, 10.7M citations

96% related

University of Washington
305.5K papers, 17.7M citations

96% related

Yale University
220.6K papers, 12.8M citations

96% related

Cornell University
235.5K papers, 12.2M citations

95% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202359
2022177
20211,841
20201,762
20191,653
20181,569